Earnings Feed
Start Free
Home/Filings/4/0001140361-13-035677
4//SEC Filing

REXAHN PHARMACEUTICALS, INC. 4

Accession 0001140361-13-035677

$IRDCIK 0001228627operating
View on SEC.govCompany Profile

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 6:01 PM ET

Size

15.8 KB

Accession

0001140361-13-035677

Insider Transaction Report

Form 4
Period: 2013-09-09
REXAHN PHARMACEUTICALS, INC.RNN
Jeong Tae Heum
DirectorCFO
Transactions
  • Tax Payment

    Common Stock

    2013-09-09$0.46/sh−78,861$36,000→ 576,139 total
  • Sale

    Common Stock

    2013-09-09$0.46/sh−71,139$32,475→ 505,000 total
  • Exercise/Conversion

    Common Stock

    2013-09-09$0.24/sh+150,000$36,000→ 655,000 total
  • Exercise/Conversion

    Stock Option (right to purchase)

    2013-09-09−150,000→ 0 total
    Exercise: $0.24Exp: 2013-10-04→ Common Stock (150,000 underlying)
Holdings

  • Stock Option (right to purchase)

    Exercise: $0.31Exp: 2023-03-01→ Common Stock (250,000 underlying)
    250,000

  • Stock Option (right to purchase)

    Exercise: $0.80Exp: 2015-01-20→ Common Stock (500,000 underlying)
    500,000

  • Stock Option (right to purchase)

    Exercise: $0.78Exp: 2018-12-11→ Common Stock (250,000 underlying)
    250,000

  • Stock Option (right to purchase)

    Exercise: $0.80From: 2005-12-01Exp: 2013-10-04→ Common Stock (100,000 underlying)
    100,000
Footnotes (6)
  • [F1]Reflects shares withheld by the issuer at the weighted average sales price of 0.4565 per share to fund the cashless exercise of 150,000 options.
  • [F2]Options will vest and be exercisable based on the following schedule: 75,000 on March 1, 2014, 75,000 on March 1, 2015, and 100,000 on March 1, 2016.
  • [F3]Options vested and became exercisable based on the following schedule 75,000 on December 11, 2009, 75,000 on December 11, 2010, and 100,000 on December 11, 2011.
  • [F4]Options vested and became exercisable based on the following schedule 150,000 on January 20, 2006, 150,000 on January 20, 2007, and 200,000 on January 20, 2008.
  • [F5]Options were due to expire on August 5, 2003, however, the Compensation Committee of the Board of Directors of Rexahn Pharmaceuticals, Inc. (the "Company") extended the expiration date because the Company was in a blackout period at that time. The expiration date was extended to 30 days from the end of the blackout period, which is October 4, 2013.
  • [F6]Options vested and became exercisable based on the following schedule 75,000 on December 1, 2003 and 75,000 on December 1, 2004.

Documents

1 file

Issuer

REXAHN PHARMACEUTICALS, INC.

CIK 0001228627

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001228627

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 6:01 PM ET
Size
15.8 KB
View on SEC.gov